Zymeworks Inc. Common Stock
Zymeworks Inc., a clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID). Its therapeutic platforms and fully integrated drug development engine provides the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. … Read more
Zymeworks Inc. Common Stock (ZYME) - Net Assets
Latest net assets as of September 2025: $320.06 Million USD
Based on the latest financial reports, Zymeworks Inc. Common Stock (ZYME) has net assets worth $320.06 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($397.27 Million) and total liabilities ($77.20 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $320.06 Million |
| % of Total Assets | 80.57% |
| Annual Growth Rate | 23.88% |
| 5-Year Change | -17.36% |
| 10-Year Change | 1757.38% |
| Growth Volatility | 358.94 |
Zymeworks Inc. Common Stock - Net Assets Trend (2014–2024)
This chart illustrates how Zymeworks Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Zymeworks Inc. Common Stock (2014–2024)
The table below shows the annual net assets of Zymeworks Inc. Common Stock from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $338.77 Million | -27.12% |
| 2023-12-31 | $464.81 Million | -5.71% |
| 2022-12-31 | $492.96 Million | +97.90% |
| 2021-12-31 | $249.09 Million | -39.23% |
| 2020-12-31 | $409.92 Million | +66.85% |
| 2019-12-31 | $245.68 Million | +36.12% |
| 2018-12-31 | $180.49 Million | +55.02% |
| 2017-12-31 | $116.43 Million | +1193.36% |
| 2016-12-31 | $9.00 Million | -50.64% |
| 2015-12-31 | $18.24 Million | -54.15% |
| 2014-12-31 | $39.78 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Zymeworks Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 78558300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.02 Billion | 302.21% |
| Other Comprehensive Income | $-6.95 Million | -2.05% |
| Other Components | $152.25 Million | 44.94% |
| Total Equity | $338.77 Million | 100.00% |
Zymeworks Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Zymeworks Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Iren S.p.A.
LSE:0MUN
|
$1.78 Billion |
|
China First Heavy Industries
SHG:601106
|
$1.78 Billion |
|
Orpea SA
PINK:ORPEF
|
$1.78 Billion |
|
ShenZhen Yitoa Intelligent Control Co Ltd
SHE:300131
|
$1.78 Billion |
|
Jungheinrich Aktiengesellschaft
PINK:JGHAF
|
$1.78 Billion |
|
Zhongsheng Group Holdings Limited
PINK:ZHSHF
|
$1.77 Billion |
|
Himax Technologies Inc
NASDAQ:HIMX
|
$1.77 Billion |
|
GCC S.A.B. DE C.V.
F:AK4
|
$1.77 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zymeworks Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 464,806,000 to 338,768,000, a change of -126,038,000 (-27.1%).
- Net loss of 122,695,000 reduced equity.
- Share repurchases of 30,051,000 reduced equity.
- Other comprehensive income decreased equity by 349,000.
- Other factors increased equity by 27,057,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-122.69 Million | -36.22% |
| Share Repurchases | $30.05 Million | -8.87% |
| Other Comprehensive Income | $-349.00K | -0.1% |
| Other Changes | $27.06 Million | +7.99% |
| Total Change | $- | -27.12% |
Book Value vs Market Value Analysis
This analysis compares Zymeworks Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.38x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 11.99x to 5.38x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $2.00 | $24.04 | x |
| 2015-12-31 | $0.92 | $24.04 | x |
| 2016-12-31 | $0.46 | $24.04 | x |
| 2017-12-31 | $5.46 | $24.04 | x |
| 2018-12-31 | $-4.99 | $24.04 | x |
| 2019-12-31 | $6.46 | $24.04 | x |
| 2020-12-31 | $8.14 | $24.04 | x |
| 2021-12-31 | $4.78 | $24.04 | x |
| 2022-12-31 | $7.55 | $24.04 | x |
| 2023-12-31 | $6.75 | $24.04 | x |
| 2024-12-31 | $4.46 | $24.04 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zymeworks Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -36.22%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -160.80%
- • Asset Turnover: 0.16x
- • Equity Multiplier: 1.37x
- Recent ROE (-36.22%) is above the historical average (-67.91%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -32.55% | -774.97% | 0.03x | 1.27x | $-16.92 Million |
| 2015 | -105.10% | -198.45% | 0.42x | 1.27x | $-20.99 Million |
| 2016 | -375.57% | -307.10% | 0.12x | 10.44x | $-34.71 Million |
| 2017 | -8.94% | -20.10% | 0.39x | 1.13x | $-22.05 Million |
| 2018 | 0.00% | -68.95% | 0.22x | 0.00x | $-22.03 Million |
| 2019 | -59.20% | -492.27% | 0.08x | 1.50x | $-170.01 Million |
| 2020 | -44.05% | -463.54% | 0.07x | 1.31x | $-221.54 Million |
| 2021 | -85.05% | -794.01% | 0.07x | 1.56x | $-236.75 Million |
| 2022 | 25.22% | 30.14% | 0.64x | 1.32x | $75.05 Million |
| 2023 | -25.53% | -156.13% | 0.13x | 1.25x | $-165.15 Million |
| 2024 | -36.22% | -160.80% | 0.16x | 1.37x | $-156.57 Million |
Industry Comparison
This section compares Zymeworks Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zymeworks Inc. Common Stock (ZYME) | $320.06 Million | -32.55% | 0.24x | $1.78 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |